Comparison of the Efficacy, Safety, Pharmacokinetic and Immunogenicity of UJVIRA (ZRC-3256, Trastuzumab Emtansine) With the Kadcyla (Trastuzumab Emtansine) in the Treatment of HER2-Positive Metastatic Breast Cancer: A Randomized, Open-Label, Multicenter Study in India-Reference-Cited by-同舟云学术

Comparison of the Efficacy, Safety, Pharmacokinetic and Immunogenicity of UJVIRA (ZRC-3256, Trastuzumab Emtansine) With the Kadcyla (Trastuzumab Emtansine) in the Treatment of HER2-Positive Metastatic Breast Cancer: A Randomized, Open-Label, Multicenter Study in India

Published:2021-11 Issue: Volume: Page:
ISSN:1526-8209
Container-title:Clinical Breast Cancer
language:en
Short-container-title:Clinical Breast Cancer

Author:

Chiradoni Thungappa Satheesh,Maksud Tanveer,Raut Nirmal,Nagarkar Rajnish,Batra Ullas,Kumar Sanjeev,Parmar Deven

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference17 articles.

1. World Health Organization. International agency for research on cancer. Globocan World 2018: https://gco.iarc.fr/today/data/factsheets/populations/900-world-fact-sheets.pdf. Accessed December 9, 2020

2. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review;Dawood;J Clin Oncol,2010

3. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)†;Cardoso;Ann Oncol,2014

4. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2;Slamon;N Engl J Med,2001

5. HER-2/neu oncogene protein and prognosis in breast cancer;Tandon;J Clin Oncol,1989

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Novel Size Exclusion Chromatography Method for the Analysis of Monoclonal Antibodies and Antibody–drug Conjugates by Using Sodium Iodide in the Mobile Phase;Pharmaceutical Research;2024-09-04

2. Long-Term Success With a TDM-1 Biosimilar in Recurrent HER2-Positive Breast Cancer With Multisite Metastases: A Comprehensive Case Study;Cureus;2024-08-16

3. Monoclonal antibody biosimilars for cancer treatment;iScience;2024-06

4. Trastuzumab‐based nanomedicines for breast cancer therapy: Recent advances and future opportunities;Nano Select;2024-02-17

5. The ever-expanding landscape of antibody-drug conjugates (ADCs) in solid tumors: A systematic review;Critical Reviews in Oncology/Hematology;2023-12